Gest

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study

SYDNEY, Australia--(BUSINESS WIRE)--Jun 27, 2007 - PrimeCell(TM)Therapeutics LLC (http://www.primecelltherapeutics.com) todayannounced that it provided research support and pre-clinicalstudies for a clinical trial to assess the safety, feasibility andefficacy of implanting autologous bone marrow stem cells intospinal cord injury (SCI) patients. Dr. Luis Geffner presented a preliminary rep...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates

'Superbug' Prevalence Data from 1,237 Facilities DemonstratesPublic Health Threat; Colonization and Infections Span All States,Across Healthcare Facility Units SAN JOSE, Calif., June 25, 2007 /PRNewswire-USNewswire/ -- TheAssociation for Professionals in Infection Control and Epidemiology(APIC) today released initial results from a nationwide study of1,237 U.S. healthcare facilities, exam...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- QuigleyPharma, <a target="_blank" href="http://www.quigleypharma.com/">www.QuigleyPharma.com , a whollyowned subsidiary of The Quigley Corporation announced today that ithas completed a follow-up study to evaluate the impact of QR-443 onlevels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in acachexia model. This new data...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

Clear Anti-Inflammatory Activity Demonstrated Among Patients withActive Disease MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ --ChemoCentryx, Inc., a clinical-stage biopharmaceutical companyfocused on discovering, developing and commercializingorally-administered therapeutics that target the chemokine system,presented data today from the company's Phase 2 clinical trial ofTraficet-EN...

Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse

Prevalence of Alcohol Abuse Among ADHD Patients Nearly Triple Thatof General Population, Affecting Approximately 1 Million People INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall/ -- Data from arecent clinical study showed Strattera(R) (atomoxetine HCl)improved symptoms of Attention- Deficit/Hyperactivity Disorder(ADHD) in patients with comorbid alcohol abuse disorder, suggestingADHD can...

New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon

SAN DIEGO, May 22, 2007 /PRNewswire/ -- A new study presentedtoday showed that ramelteon did not impair middle-of-the-nightbalance, mobility or memory performance in older adults withinsomnia, relative to placebo. This study also demonstrated, as inprevious studies, that patients treated with zolpidem did haveimpaired performances on these measures, as compared to placebo.The results of...

New Data Suggests Less Abuse-Related Effects For OROS Methylphenidate

Two New Studies Highlight Potential Benefit of Unique OROS(R)Formulation SAN DIEGO, May 23, 2007 /PRNewswire/ -- Stimulant drug abuseremains an ongoing concern for parents and physicians who prescribemedications to treat Attention Deficit Hyperactivity Disorder(ADHD). Data presented on Tuesday at the 160th Annual Meeting ofthe American Psychiatric Association highlighted findings thatlon...

Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- MGI PHARMA, INC.(NASDAQ:MOGN), a biopharmaceutical company focused in oncology andacute care, today announced the presentation of results of asuccessful pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection in patients undergoing colonoscopy. Primary andsecondary efficacy endpoint results, as well as safety data, werepresented at...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/-- Napo Pharmaceuticals, Inc., , which focuses on the developmentand commercialization of proprietary pharmaceuticals for the globalmarketplace in collaboration with local partners, announced thatTrine Pharmaceuticals, Inc. ("Trine") is presenting a posterdetailing the results of a Phase 2a study conducted in 2006 forcrofele...

PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week

Nuvion Antibody Led to a Sustained Response and Remission inFollow-up to Phase 1 and Phase 1/2 studies and Was AdequatelyTolerated in Patients with IV Steroid-Refractory Ulcerative Colitis FREMONT, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- Datapresented at the Digestive Disease Week (DDW) meeting this week inWashington D.C. by Dr. William Sandborn from the Mayo Clinicsuggest that Nuv...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

AstraZeneca Focuses Research on Growing Childhood Condition WASHINGTON, May 22, 2007 /PRNewswire-FirstCall/ -- AstraZenecawill present several studies today regarding pediatric patientswith gastroesophageal reflux disease (GERD) during oral and postersessions at the annual Digestive Disease Week meeting held at theWashington Convention Center. The studies being presented further sup...

Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder

Relationship Between Ability to Function and Treatment of Anxiousand Painful Physical Symptoms Studied INDIANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ -- Datasuggest that patients with generalized anxiety disorder (GAD)treated with Cymbalta(R) (duloxetine HCl) experienced improvedability to perform everyday activities at home, work and in socialsituations compared to sugar pill. These i...

Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype1 patients support development of Omega DUROS(R) continuousdelivery therapy WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics,Inc., a privately held biopharmaceutical company, today announcedthe presentation of final results from a Phase 2 study comparingthe combination of injectable omega interferon and ribav...

Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist

Findings Show Compliance with Medication Instructions butUnderscore Need for Improved Patient Communication, LifestyleManagement and More Healthcare Provider Efforts to Control ElevatedBlood Pressure NEW YORK, May 19, 2007 /PRNewswire/ -- Results of a surveyconducted by Harris Interactive(R) for the Hypertension EducationFoundation (HEF) were presented at the American Society ofHypertens...

InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting

Reports 'Picomolar' Potency and Slow Dissociation from HCVProtease WASHINGTON, May 21, 2007 /PRNewswire-FirstCall via COMTEX NewsNetwork/ -- InterMune, Inc. (Nasdaq: ITMN) today presented newpreclinical data on the company's Hepatitis C virus (HCV) NS3/4Aprotease inhibitor, ITMN-191, during a scientific session of theDigestive Disease Week (DDW) meeting being held May 19-24 inW...

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Roche today announcedresults of a small study demonstrating that all patients whodiscontinued treatment with Peg-Intron(R) (peginterferon alfa-2b)and ribavirin due to adverse events within the first 12 weeks, wereable to complete 12 weeks of treatment with PEGASYS(R)(peginterferon alfa-2a) and ribavirin. Furthermore, 92 percent ofthese patients we...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

KENILWORTH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A totalof 20 oral and poster presentations on clinical studies withSchering-Plough's hepatitis products, including PEGINTRON(TM)(peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combinationtherapy for chronic hepatitis C virus (HCV) infection, as well asboceprevir (SCH 503034), the company's investigational oral HCVprotease i...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ -MIGENIX Inc. , a clinical-stage developer of drugs for infectiousdiseases will make a presentation of results from a recenthepatitis C Phase II combination therapy study (see April 11, 2007press release) in a non-responder patient population at DigestiveDisease Week (DDW) 2007 being held in Washington, DC May 19-24,2007. Dr. K...

Salix Pharmaceuticals Previews Digestive Disease Week 2007

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of18 investigator-initiated trials related to the Company's productswill be presented at Digestive Disease Week(R) 2007, which will beheld May 19-24, 2007. Digestive Disease Week is considered thelargest and most prestigious meeting in the world for the GIprofessional. Every...

Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntington's Disease

BOSTON--(BUSINESS WIRE)--May 3, 2007 - New data show theinvestigational drug tetrabenazine maintained reduction of choreaassociated with Huntington's disease (HD) up to 80 weeks in thosepatients who successfully completed treatment in a 13-week trial.These data suggest that tetrabenazine can be used successfully tosustain reduced chorea burden in long-term use. "These findings demonstrate...

Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain

New Analysis Examines Impact of Pain on Sleep Interference INDIANAPOLIS, May 03, 2007 /PRNewswire-FirstCall/ -- Data from apooled analysis of three studies suggest that in patients with paincaused by diabetic nerve damage, or diabetic peripheral neuropathy,who are treated with Cymbalta (duloxetine HCl), improvements inboth average daily pain and night pain severity were associatedwith les...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting

CAMBRIDGE, Mass., April 18, 2007 /PRNewswire-FirstCall/ --Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engagedin the discovery, development and commercialization of drugs forthe treatment of human viral and other infectious diseases,announced today that 11 abstracts have been accepted forpresentation at the 2007 Digestive Disease Week (DDW) meeting, tobe held in Washington...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced that the Eastern Cooperative Oncology Group(ECOG) has reported that its Data Monitoring Committee's (DMC)review of preliminary results from a large, randomized clinicaltrial for patients with newly diagnosed multiple myeloma has foundthat the use of a low dose of dexamethasone (Decadron) incombination wit...

Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control

52-Week Trial Maintained Improvement in Personal and SocialPerformance COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ --Longer-term treatment with INVEGA(TM) (paliperidone)Extended-Release Tablets, a new once daily oral medication forschizophrenia, helped many patients effectively control theirsymptoms and maintain their improvements in personal and socialfunctioning....

ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent

Compound Could Be Utilized as an Adjuvant and Play Key Role in theTreatment of Influenza and Cancer SCOTTSDALE, Ariz., March 20, 2007 /PRNewswire-FirstCall/ --ImmuneRegen BioSciences, a wholly owned subsidiary of IRBioSciences Holdings, Inc. , announced today that data obtained bythe Company on its Substance P analog, Homspera, suggests that thecompound has potential value as a co-therape...